TORNTPHARM.NS Profit & Loss
Torrent Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 00:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹9,620.00 Cr. | ₹10,728.00 Cr. | ₹11,516.00 Cr. | ₹13,980.00 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹45.00 Cr. | ₹58.00 Cr. | ₹23.00 Cr. | ₹-94.00 Cr. | OtherIncome |
| Total Income | ₹9,665.00 Cr. | ₹10,786.00 Cr. | ₹11,539.00 Cr. | ₹13,886.00 Cr. | Income |
| Cost of Materials Consumed | ₹1,480.00 Cr. | ₹1,657.00 Cr. | ₹1,520.00 Cr. | ₹1,758.00 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹1,089.00 Cr. | ₹1,184.00 Cr. | ₹1,531.00 Cr. | ₹1,619.00 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹166.00 Cr. | ₹-155.00 Cr. | ₹-275.00 Cr. | ₹11.00 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹1,678.00 Cr. | ₹1,984.00 Cr. | ₹2,203.00 Cr. | ₹2,671.00 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹333.00 Cr. | ₹354.00 Cr. | ₹252.00 Cr. | ₹385.00 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹707.00 Cr. | ₹808.00 Cr. | ₹795.00 Cr. | ₹1,119.00 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹2,365.00 Cr. | ₹2,690.00 Cr. | ₹2,816.00 Cr. | ₹3,362.00 Cr. | OtherExpenses |
| Total Expenses | ₹7,818.00 Cr. | ₹8,522.00 Cr. | ₹8,842.00 Cr. | ₹10,925.00 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹1,847.00 Cr. | ₹2,264.00 Cr. | ₹2,697.00 Cr. | ₹2,961.00 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹88.00 Cr. | ₹-24.00 Cr. | ₹-89.00 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹1,847.00 Cr. | ₹2,352.00 Cr. | ₹2,673.00 Cr. | ₹2,872.00 Cr. | ProfitBeforeTax |
| Tax Expense | ₹602.00 Cr. | ₹696.00 Cr. | ₹762.00 Cr. | ₹734.00 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹1,245.00 Cr. | ₹1,656.00 Cr. | ₹1,911.00 Cr. | ₹2,138.00 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹1,245.00 Cr. | ₹1,656.00 Cr. | ₹1,911.00 Cr. | ₹2,163.00 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹36.79 | ₹48.94 | ₹56.47 | ₹63.92 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹36.79 | ₹48.94 | ₹56.47 | ₹63.92 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from TORNTPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).